These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31950021)

  • 81. Research Status of Mouse Models for Non-Small-Cell Lung Cancer (NSCLC) and Antitumor Therapy of Traditional Chinese Medicine (TCM) in Mouse Models.
    Chen H; Zheng M; Zhang W; Long Y; Xu Y; Yuan M
    Evid Based Complement Alternat Med; 2022; 2022():6404853. PubMed ID: 36185084
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Yuanhuacin and Related Anti-Inflammatory and Anticancer Daphnane Diterpenes from Genkwa Flos-An Overview.
    Bailly C
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204693
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer.
    Xu C; Zhang L; Wang D; Jiang S; Cao D; Zhao Z; Huang M; Jin J
    Cell Death Discov; 2021 Nov; 7(1):353. PubMed ID: 34775471
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications.
    Wium M; Ajayi-Smith AF; Paccez JD; Zerbini LF
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33806258
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Aptamers in Non-Small Cell Lung Cancer Treatment.
    Wieleba I; Wojas-Krawczyk K; Krawczyk P
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32659994
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment.
    Li J; Kwok HF
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32549388
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer.
    Jeong I; Song J; Bae SY; Lee SK
    J Cancer Prev; 2019 Dec; 24(4):217-223. PubMed ID: 31950021
    [TBL] [Abstract][Full Text] [Related]  

  • 89.
    Han SY; Zhao W; Han HB; Sun H; Xue D; Jiao YN; He XR; Jiang ST; Li PP
    Oncotarget; 2017 Aug; 8(34):56893-56905. PubMed ID: 28915640
    [TBL] [Abstract][Full Text] [Related]  

  • 90. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
    Yang YM; Jang Y; Lee SH; Kang B; Lim SM
    Lung Cancer; 2020 Aug; 146():70-77. PubMed ID: 32521387
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
    Park K; Chang GC; Curigliano G; Lim WT; Soo RA; Molina-Vila MA; Cattan V; Darville H; Gandossi E; Smutna V; Sudey I; Viteri S
    Lung Cancer; 2021 May; 155():127-135. PubMed ID: 33798902
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.
    Bae SY; Hong JY; Lee HJ; Park HJ; Lee SK
    Oncotarget; 2015 Apr; 6(12):10146-60. PubMed ID: 25760142
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
    Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
    Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
    [TBL] [Abstract][Full Text] [Related]  

  • 94. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
    Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV
    Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
    Zhang Z; Lee JC; Lin L; Olivas V; Au V; LaFramboise T; Abdel-Rahman M; Wang X; Levine AD; Rho JK; Choi YJ; Choi CM; Kim SW; Jang SJ; Park YS; Kim WS; Lee DH; Lee JS; Miller VA; Arcila M; Ladanyi M; Moonsamy P; Sawyers C; Boggon TJ; Ma PC; Costa C; Taron M; Rosell R; Halmos B; Bivona TG
    Nat Genet; 2012 Jul; 44(8):852-60. PubMed ID: 22751098
    [TBL] [Abstract][Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.